Expression of Cyclooxygenase-2, Fas and Fas Ligand in Pulmonary Adenocarcinoma and Atypical Adenomatous Hyperplasia

Anticancer Research

Volumn 23, Issue 6 D, 2003, Pages 5069-5073

  Takigawa, Nagio ^a,b   Ida, Mikiko ^a   Segawa, Yoshihiko ^a   Nakata, Masao ^a   Mandai, Koichi ^a   Kishino, Daizo ^a   Fujiwara, Keiichi ^a   Saeki, Hideyuki ^a   Takashima, Shigemitsu ^a   Eguchi, Kenji ^a  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^b National Hospital Organization   (Japan)

Author keywords

Adenocarcinoma; Cyclooxygenase 2; Fas; Lung neoplasms; Precancerous conditions

Indexed keywords

CYCLOOXYGENASE 2; FAS ANTIGEN; FAS LIGAND;

ADENOMA; ADULT; AGED; ARTICLE; ATYPICAL ADENOMATOUS HYPERPLASIA; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MALE; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADENOCARCINOMA; ADENOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; CYCLOOXYGENASE 2; FAS LIGAND PROTEIN; FEMALE; HUMANS; HYPERPLASIA; ISOENZYMES; LUNG; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MIDDLE AGED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 10744233316     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Smith WL, Garavito RM and DeWitt DL: Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271: 33157-33160, 1996.
2. Taketo MM: Cyclooxygenase-2 inhibitors in tumorigenesis (Part I). J Natl Cancer Inst 90: 1529-1536, 1998.
3. Taketo MM: Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 90: 1609-1620, 1998.
4. Tsujii M and Dubois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501, 1995.
5. Tsujii M, Kawano S and DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340, 1997.
6. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M and DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716, 1998.
7. Battu S, Rigaud M and Beneytout JL: Resistance to apoptosis and cyclooxygenase-2 expression in a human adenocarcinoma cell line HT29 CL. 19A. Anticancer Res 18: 3579-3584, 1998.
8. Reed JC: Dysregulation of apoptosis in cancer. J Clin Oncol 17: 2941-2953, 1999.
9. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T and Takahashi T: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinoma. Cancer Res 58: 3761-3764, 1998.
10. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H and Dubinett SM: Non-small cell lung cancer cyclooxygenase-2-independent regulation of cytokine balance in lymphocytes and macrophages: upregulation of interleukin 10 and downregulation of interleukin 12 production. Cancer Res 15: 1208-1206, 1998.
11. Nambu Y, Hughes S, Rehemtulla A, Hamstra D, Orringer MB and Beer DG: Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest 101: 1102-1110, 1998.
12. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR and Kratzke RA: Human lung carcinomas express Fas ligand. Cancer Res 15: 1007-1012, 1997.
13. Wolff H, Saokkonen K, Anttila S, Karjalainen A, Vainio H and Ristamäki A: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58: 4997-5001, 1998.
14. Kawasaki M, Noguchi M, Morikawa A, Matsuno Y, Yamada T, Hirohashi S, Kondo H and Shimosato Y: Nuclear p53 accumulation by small-sized adenocarcinomas of the lung. Pathol Int 46: 486-490, 1996.
15. Kodama T, Biyajima S, Watanabe S and Shimosato Y: Morphometric study of adenocarcinomas and hyperplastic epithelial lesions in the peripheral lung. Am J Clin Pathol 85: 146-151, 1986.
16. Miller RR: Bronchioloalveolar cell adenomas. Am J Surg Pathol 14: 904-912, 1990.
17. Nakayama H, Noguchi M, Tsuchiya R, Kodama T and Shimosato Y: Clonal growth of atypical adenomatous hyperplasia of the lung: cytofluorometric analysis of nuclear DNA content. Mod Pathol 3: 314-320, 1990.
18. Yokozaki M, Kodama T, Yokose T, Matsumoto T and Mukai K: Differentiation of atypical adenomatous hyperplasia of the lung by use of DNA ploidy and morphometric analysis. Mod Pathol 9: 1156-1164, 1996.
19. Takigawa N, Segawa Y, Nakata M, Saeki H, Mandai K, Kishino D, Shimono M, Ida M and Eguchi K: Clinical investigation of atypical adenomatous hyperplasia of the lung. Lung Cancer 9: 115-121, 1999.
20. World Health Organization. Histological Typing of Lung Tumors. 2nd edition. Geneva, World Health Organization, 1981.
21. Noguchi M and Shimosato Y: The development and progression of adenocarcinoma of the lung. In: Lung Cancer (Hansen HH editor). Boston, Kluwer Academic Publishers, 1995, pp 131-142.
22. Suzuki K, Nagai K, Yoshida J, Yokose T, Kodama T, Takahashi K, Nishimura M, Kawasaki H, Yokozaki M and Nishiwaki Y: The prognosis of resected lung carcinoma associated with atypical adenomatous hyperplasia: a comparison of prognosis of well-differentiated adenocarcinoma associated with atypical adenomatous hyperplasia and intrapulmonary metastasis. Cancer 79: 1521-1526, 1997.
23. Martini N and Melamed MR: Multiple primary lung cancers. J Thorac Cardiovasc Surg 70: 606-612, 1975.
24. UICC. TNM Classification of Malignant Tumors. New York, Wiley-Liss, 1997, pp 91-97.
25. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T and Takahashi T: Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 5: 1001-1005, 1999.
26. Watkins DN, Lenzo JC, Segal A, Garlepp MJ and Thompson PJ: Expression and localization of cyclooxygenase isoforms in non-small cell lung cancer. Eur Resp J 14: 412-418, 1999.
27. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, Kondo H and Shimosato Y: Small adenocarcinoma of the lung: histologic characteristics and prognosis. Cancer 75: 2844-2852, 1995.
28. Hosomi Y, Yokose T, Hirose Y, Nakajima R, Nagai K, Nishiwaki Y and Ochiai A: Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 30: 73-81, 2000.
29. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK and Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952, 2000.
30. Koomägi R and Volm M: Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer: its prognostic and predictive relevance. Int J Cancer (Pred Oncol) 84: 239-243, 1999.
31. Uramoto H, Osaki T, Inoue M, Taga S, Takenoyama M, Hanagiri T, Yoshino I, Nakanishi R, Ichiyoshi Y and Yasumoto K: Analysis of Fas and Fas ligand expression and function in lung cancer cell lines. Eur J Cancer 35: 1462-1465, 1999.
32. Volm M and Koomägi R: The implications of proliferation and apoptosis for lung cancer metastasis. Oncol Rep 6: 373-376, 1999.
33. Suzuki K, Yokose T, Yoshida J, Nishimura M, Takahashi K, Nagai K and Nishiwaki Y: Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg 69: 893-897, 2000.